Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma

Molecular and Cellular Biology

Volumn 25, Issue 13, 2005, Pages 5675-5686

  Raval, Raju R ^a,d   Lau, Kah Weng ^a   Tran, Maxine G B ^c   Sowter, Heidi M ^b   Mandriota, Stefane J ^a   Li, Ji Liang ^b   Pugh, Christopher W ^a   Maxwell, Patrick H ^c   Harris, Adrian L ^b   Ratcliffe, Peter J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ISOPROTEIN; PROTEIN BNIP3; PROTEIN SUBUNIT; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; TUMOR GROWTH; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYCLINS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HIPPEL-LINDAU DISEASE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 20744445650     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.25.13.5675-5686.2005     Document Type: Article

References (49)

1. Baba, M., S. Hirai, H. Yamada-Okabe, K. Hamada, H. Tabuchi, K. Kobayashi, K. Kondo, M. Yoshida, A. Yamashita, T. Kishida, N. Nakaigawa, Y. Nagashima, Y. Kubota, M. Yao, and S. Ohno. 2003. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of cyclin D1 expression through hypoxia-inducible factor. Oncogene 22:2728-2738.
2. Bindra, R. S., J. R. Vasselli, R. Stearman, W. M. Linehan, and R. D. Klausner. 2002. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62:3014-3019.
3. Bruick, R. K. 2000. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97:9082-9087.
4. Bui, M. H., D. Seligson, K. R. Han, A. J. Pantuck, F. J. Dorey, Y. Huang, S. Horvath, B. C. Leibovich, S. Chopra, S. Y. Liao, E. Stanbridge, M. I. Lerman, A. Palotie, R. A. Figlin, and A. S. Belldegrun. 2003. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9:802-811.
5. Carmeliet, P., Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen, E. Keshert, and E. Keshet. 1998. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394:485-490.
6. -/- clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl. Acad. Sci. USA 98:1387-1392.
7. Ebert, T., N. H. Bander, C. L. Finstad, R. D. Ramsawak, and L. J. Old. 1990. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 50:5531-5536.
8. Harris, A. L. 2002. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47.
9. Hockel, M., and P. Vaupel. 2001. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93:266-276.
10. Hon, W. C., M. I. Wilson, K. Harlos, T. D. Claridge, C. J. Schofield, C. W. Pugh, P. H. Maxwell, P. J. Ratcliffe, D. I. Stuart, and E. Y. Jones. 2002. Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL. Nature 417:975-978.
11. Hu, C. J., L. Y. Wang, L. A. Chodosh, B. Keith, and M. C. Simon. 2003. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol. Cell. Biol. 23:9361-9374.
12. Iliopoulos, O., A. Kibel, S. Gray, and W. G. Kaelin, Jr. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-826.
13. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12:149-162.
14. Jacobs, J. J., K. Kieboom, S. Marino, R. A. DePinho, and M. van Lohuizen. 1999. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397:164-168.
15. Jiang, C., H. Lu, K. A. Vincent, S. Shankara, A. J. Belanger, S. H. Cheng, G. Y. Akita, R. A. Kelly, M. A. Goldberg, and R. J. Gregory. 2002. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HlF-1α. Physiol. Genomics 8:23-32.
16. Kaelin, W. G., Jr. 2002. Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2:673-682.
17. Kaelin, W. G., Jr. 2003. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14:2703-2711.
18. Kondo, K., W. Y. Kim, M. Lechpammer, and W. G. Kaelin, Jr. 2003. Inhibition of HIF-2α is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1:E83. [Online.]
19. Kondo, K., J. Klco, E. Nakamura, M. Lechpammer, and W. G. Kaelin, Jr. 2002. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1:237-246.
20. Koshiji, M., Y. Kageyama, E. A. Pete, I. Horikawa, J. C. Barrett, and L. E. Huang. 2004. HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23:1949-1956.
21. Kothari, S., J. Cizeau, E. McMillan-Ward, S. J. Israels, M. Bailes, K. Ens, L. A. Kirshenbaum, and S. B. Gibson. 2003. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22:4734-4744.
22. Krieg, M., R. Haas, H. Brauch, T. Acker, I. Flamme, and K. H. Plate. 2000. Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19:5435-5443.
23. Kung, A. L., S. Wang, J. M. Klco, W. G. Kaelin, and D. M. Livingston. 2000. Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6:1335-1340.
24. Kung, A. L., S. D. Zabludoff, D. S. France, S. J. Freedman, E. A. Tanner, A. Vieira, S. Cornell-Kennon, J. Lee, B. Wang, J. Wang, K. Memmert, H. U. Naegeli, F. Petersen, M. J. Eck, K. W. Bair, A. W. Wood, and D. M. Livingston. 2004. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33-43.
25. Liao, S. Y., O. N. Aurelio, K. Jan, J. Zavada, and E. J. Stanbridge. 1997. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res. 57:2827-2831.
26. Mandriota, S. J., K. J. Turner, D. R. Davies, P. G. Murray, N. V. Morgan, H. M. Sowter, C. C. Wykoff, E. R. Maher, A. L. Harris, P. J. Ratcliffe, and P. H. Maxwell. 2002. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468.
27. Maranchie, J. K., J. R. Vasselli, J. Riss, J. S. Bonifacino, W. M. Linehan, and R. D. Klausner. 2002. The contribution of VHL substrate binding and HIF-1α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1:247-255.
28. Maxwell, P. H., G. U. Dachs, J. M. Gleadle, L. G. Nicholls, A. L. Harris, I. J. Stratford, O. Hankinson, C. W. Pugh, and P. J. Ratcliffe. 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94:8104-8109.
29. Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
30. Min, J. H., H. Yang, M. Ivan, F. Gertler, W. G. Kaelin, Jr., and N. P. Pavletich. 2002. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296:1886-1889.
31. O'Rourke, J. F., Y. M. Tian, P. J. Ratcliffe, and C. W. Pugh. 1999. Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1α. J. Biol. Chem. 274:2060-2071.
32. Park, S. K., A. M. Dadak, V. H. Haase, L. Fontana, A. J. Giaccia, and R. S. Johnson. 2003. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1α (HIF-1α): role of cytoplasmic trapping of HIF-2α. Mol. Cell. Biol. 23:4959-4971.
33. Rapisarda, A., B. Uranchimeg, D. A. Scudiero, M. Selby, E. A. Sausville, R. H. Shoemaker, and G. Melillo. 2002. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:4316-4324.
34. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14:34-44.
35. Ryan, H. E., J. Lo, and R. S. Johnson. 1998. HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005-3015.
36. Seagroves, T. N., H. E. Ryan, H. Lu, B. G. Wouters, M. Knapp, P. Thibault, K. Laderoute, and R. S. Johnson. 2001. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol. Cell. Biol. 21:3436-3444.
37. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-732.
38. Sherr, C. J. 1996. Cancer cell cycles. Science 274:1672-1677.
39. Sowter, H. M., R. R. Raval, J. W. Moore, P. J. Ratcliffe, and A. L. Harris. 2003. Predominant role of hypoxia-inducible transcription factor (Hif)-α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res. 63:6130-6134.
40. Tanimoto, K., Y. Makino, T. Pereira, and L. Poellinger. 2000. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19:4298-4309.
41. Thrash-Bingham, C. A., and K. D. Tartof. 1999. aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. J. Natl. Cancer Inst. 91:143-151.
42. Tian, H., S. L. McKnight, and D. W. Russell. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:72-82.
43. Vande Velde, C., J. Cizeau, D. Dubik, J. Alimonti, T. Brown, S. Israels, R. Hakem, and A. H. Greenberg. 2000. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell. Biol. 20:5454-5468.
44. Warnecke, C., Z. Zaborowska, J. Kurreck, V. A. Erdmann, U. Frei, M. Wiesener, and K. U. Eckardt. 2004. Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells. FASEB J. 18:1462-1464.
45. Wiesener, M. S., H. Turley, W. E. Allen, C. Willam, K. U. Eckardt, K. L. Talks, S. M. Wood, K. C. Gatter, A. L. Harris, C. W. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 1998. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1α. Blood 92:2260-2268.
46. Wykoff, C. C., C. Sotiriou, M. E. Cockman, P. J. Ratcliffe, P. Maxwell, E. Liu, and A. L. Harris. 2004. Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br. J. Cancer 90:1235-1243.
47. Zatyka, M., N. F. da Silva, S. C. Clifford, M. R. Morris, M. S. Wiesener, K. U. Eckardt, R. S. Houlston, F. M. Richards, F. Latif, and E. R. Maher. 2002. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 62:3803-3811.
48. Zavada, J., Z. Zavadova, S. Pastorekova, F. Ciampor, J. Pastorek, and V. Zelnik. 1993. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer 54:268-274.
49. -/- tumors. Mol. Cancer Res. 2:89-95.